					ATTORNEY DOCKET	APPLICATION NO.		
INFORMATION DISCLOSURE STATEMENT					25352-0022	10/082,801		
OIPE (37 CFR 1.56, 1.97, and 1.98)					APPLICANT(S)			
					Hugo O. Villar, et al.			
SEP 1 8 2002 SHEET 1 OF 1				FILING DATE	GROUP			
021 10	2002 S	·)			February 8, 2002	1645		
U.S. PATENT DOCUMENTS								
† EX P	REF. #	PATENT NUMBER	DATE (MO/YR)		NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)	
						<u> </u>		
FOREIGN PATENT DOCUMENTS								
t ex'r Immal	* REF. #	PATENT NUMBER	DATE (MO/YR)		COUNTRY		TRANSLATION (YES/NO)	
(6)	19	00/76982	12/2000		PCT			
OTHER DOCUMENTS								
† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)						
8	20	E. Chotkowska et al., "Cytotoxic properties of nitro derivatives of 9-aminoacridine in cultures of <i>Euglena gracilis</i> ", <i>Arch. Immunol. Ther. Exp.</i> , 20 (2), 289-294 (1972)						
C	21	C. Radzikowski et al., "A search for antitumor compounds", Arch. Immunol. Ther. Exp., 17(1), 86-98 (1969)						
3	22	B. Wysocka-Skrezela et al., "Research on tumour inhibiting compounds. Part LXXII. Reduction of 1-nitro-9(3-dimethylaminopropylamino)-acridine by sodium borohydride", <i>Pol. J. Chem.</i> , 55 (7-8), 1735-1736 (1981)						
	23	M. K. Piestrzeniewicz et al., "Inhibition of RNA synthesis <i>in vitro</i> by acridines - relation between structure and activity", <i>Z. Naturforsch.</i> , 53c (5-6), 359-368 (1998)						
3	C. Radzikowski et al., "The cytostatic and cytotoxic effect of 1-nitro-9-aminacridine derivatives", Proc. 5th Int'l Congr. Chemother., 2(1), 263-266 (1967)							
EXAMINER'S SIGNATURE DATE CONSIDERED								
8-15-9								
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in								

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant*.

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).

RECEIVED

SEP 1 9 2002

TECH CENTER 1600/2900